Literature DB >> 17071924

Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia.

Isabelle Le Ber1, Eric Guedj, Audrey Gabelle, Patrice Verpillat, Magali Volteau, Catherine Thomas-Anterion, Marielle Decousus, Didier Hannequin, Pierre Véra, Lucette Lacomblez, Agnès Camuzat, Mira Didic, Michèle Puel, Jean-Albert Lotterie, Véronique Golfier, Anne-Marie Bernard, Martine Vercelletto, Christine Magne, François Sellal, Izzie Namer, Bernard-François Michel, Jacques Pasquier, François Salachas, Jean Bochet, Alexis Brice, Marie-Odile Habert, Bruno Dubois.   

Abstract

We conducted a French multicentric cross-sectional study to describe in detail the demographic, neurological and behavioural characteristics of the frontal variant of frontotemporal dementia (fvFTD) and to characterize the pattern of brain perfusion SPECT in comparison to a healthy control group. A total of 68 fvFTD patients had technetium-99m-ECD brain perfusion SPECT at inclusion, 61 of which also underwent an in-depth evaluation including 70 items assessing behaviour, language and affect/emotion at onset and at inclusion. The mean age-at-onset was 60.4 +/- 7.8 years (35-75). Twenty-six per cent of the patients were older than 65 at onset. A positive familial history consistent with an autosomal dominant inheritance was found in 18% of the patients. At onset, the behavioural profile was predominantly inert in 25% of the patients, disinhibited in 18% and mixed in others. The behavioural features progressed to predominantly mixed or inert forms. Although, inertia was associated with predominant medial frontal and cingulate hypoperfusion, and patients with disinhibition exhibited predominant ventromedial prefrontal and temporal hypoperfusion, there were no major clinical differences between disinhibited and inert patients. Forty-five per cent of the deceased patients survived <6 years (short survival), and 34% of the patients survived >8 years (long survival). This shows that the final outcome of fvFTD is highly variable. No clinical factors predictive of short or long survival were identified. Unexpected, however, was the finding that brainstem hypoperfusion distinguished patients with a short survival from patients with long survival. In conclusion, this study shows that fvFTD is clinically a rather homogeneous entity. It also provides evidence that different behavioural presentations at onset are related to different anatomical localizations of degenerative damage. Finally, it demonstrates the prognostic value of brainstem hypoperfusion in a subgroup of patients with a short survival.

Entities:  

Mesh:

Year:  2006        PMID: 17071924     DOI: 10.1093/brain/awl288

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  46 in total

1.  Heritability in frontotemporal dementia: more missing pieces?

Authors:  Kieren Po; Felicity V C Leslie; Natalie Gracia; Lauren Bartley; John B J Kwok; Glenda M Halliday; John R Hodges; James R Burrell
Journal:  J Neurol       Date:  2014-08-26       Impact factor: 4.849

2.  Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates.

Authors:  G Zamboni; E D Huey; F Krueger; P F Nichelli; J Grafman
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

3.  EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.

Authors:  Ozlem L Kapucu; Flavio Nobili; Andrea Varrone; Jan Booij; Thierry Vander Borght; Kjell Någren; Jacques Darcourt; Klaus Tatsch; Koen J Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

4.  Predicting functional decline in behavioural variant frontotemporal dementia.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Matthew L Senjem; Bradley F Boeve; David S Knopman; Glenn E Smith; Robert J Ivnik; Clifford R Jack; Ronald C Petersen
Journal:  Brain       Date:  2011-01-20       Impact factor: 13.501

5.  Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD.

Authors:  Silvia Morbelli; Michela Ferrara; Francesco Fiz; Barbara Dessi; Dario Arnaldi; Agnese Picco; Irene Bossert; Ambra Buschiazzo; Jennifer Accardo; Lorena Picori; Nicola Girtler; Paola Mandich; Marco Pagani; Gianmario Sambuceti; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-01       Impact factor: 9.236

Review 6.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 7.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

Review 8.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

9.  Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.

Authors:  David J Irwin; Corey T McMillan; EunRan Suh; John Powers; Katya Rascovsky; Elisabeth M Wood; Jon B Toledo; Steven E Arnold; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Murray Grossman
Journal:  Neurology       Date:  2014-07-03       Impact factor: 9.910

10.  Rostro-caudal Architecture of the Frontal Lobes in Humans.

Authors:  Michel Thiebaut de Schotten; Marika Urbanski; Benedicte Batrancourt; Richard Levy; Bruno Dubois; Leonardo Cerliani; Emmanuelle Volle
Journal:  Cereb Cortex       Date:  2017-08-01       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.